intoxicant.wiki2catechol4school
Serotonin 5-HT2A receptor agonist · Serotonergic psychedelic · Hallucinogen

BMB-202

Original Wikipedia articleen.wikipedia.org/wiki/BMB-202 revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Overview

BMB-202 is a selective serotonin 5-HT2A receptor agonist and psychedelic drug of the N-benzylphenethylamine family which is under development for the treatment of depressive disorders and post-traumatic stress disorder (PTSD). It is taken orally.[1–7] WP

Drug class

Serotonin 5-HT2A receptor agonist Serotonergic psychedelic Hallucinogen WP

From the Wikipedia article's infobox.

Pharmacology

Pharmacodynamics

BMB-202 acts as a highly selective full agonist of the serotonin 5-HT2A receptor. In terms of EC₅₀ (half-maximal effective concentration) values, it shows 36- to 40-fold selectivity for activation of the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor and 500-fold selectivity for activation of the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor. It has been claimed by its developer that BMB-202 is the most selective serotonin 5-HT2A receptor agonist yet to be discovered or to be in development, at least as of late 2024.[1–7] WP

BMB-202 induces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in animals. Hence, it is putatively hallucinogenic in humans. As with other psychedelics like psilocybin, the HTR induced by BMB-202 shows a biphasic or inverted U-shaped dose–response curve.[3] WP

The drug shows a pharmacokinetic profile of high peak levels, rapid metabolic clearance, and a short elimination half-life in animals. It is predicted that BMB-202 will have a short half-life of less than 2 hours and short duration of 1 to 2 hours in humans. In relation to this, the drug is described as a "fast-on-fast-off" compound. The expected short duration of BMB-202 is analogous to the short duration of dimethyltryptamine (DMT). Short-acting psychedelics like DMT and BMB-202 may be more suitable for use in clinical therapeutic settings. BMB-202 is also described as having rapid absorption and brain distribution, high bioavailability, and significant first-pass metabolism resulting in it being fast-acting and having a short duration.[3][5–9] WP

Research

Research

BMB-202 is under development by Bright Minds Biosciences. As of September 2025, it is in the preclinical research stage of development for treatment of depressive disorders and PTSD.[1][2] WP

Chemistry

Awaiting sourceFormula, structure and identifiers from PubChem.

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings
Awaiting sourceExperience Vault listing and report categories.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

  1. Journal / agency BMB 202. 24 April 2023
  2. Other Delving into the Latest Updates on BMB-202 with Synapse. 29 October 2024
  3. Other Vasilkevich A, Halberstadt AL, Duan J, Merritt CR, Cunningham KA, McCorvy J, Kozikowski A, Pedersen J. Novel 5-HT2A selective agonists with well-characterized PK profile and short duration of action. October 2024
  4. Other Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023. 27 February 2023
  5. Other Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202. 19 April 2023
  6. Other Bright Minds Biosciences. Bright Minds Novel Drugs for Targeted Treatment of CNS & Neuropsychiatric Disorders September 2024 (BMB Investor Deck). September 2024
  7. Other Vasilkevich A, Lovera A, Duan J, McDonald I, Collins SD, Pedersen JT. Overview of Bright Minds Biosciences: Pioneering Serotonin Pharmacology. 7 December 2025
  8. Journal / agency Cameron LP, Olson DE. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT). ACS Chem Neurosci. October 2018. doi:10.1021/acschemneuro.8b00101 · PMID 30036036
  9. Journal / agency Chaves C, Dos Santos RG, Dursun SM, Tusconi M, Carta MG, Brietzke E, Hallak JE. Why N, N-Dimethyltryptamine (DMT) Matters: Unique Features and Therapeutic Potential Beyond Classical Psychedelics. Frontiers in Psychiatry. 2024. doi:10.3389/fpsyt.2024.1485337 · PMID 39568756 · PMC11576444

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.